REV7 counteracts DNA double-strand break resection and affects PARP inhibition

Error-free repair of DNA double-strand breaks (DSBs) is achieved by homologous recombination (HR), and BRCA1 is an important factor for this repair pathway. In the absence of BRCA1-mediated HR, the administration of PARP inhibitors induces synthetic lethality of tumour cells of patients with breast or ovarian cancers. Despite the benefit of this tailored therapy, drug resistance can occur by HR restoration. Genetic reversion of BRCA1-inactivating mutations can be the underlying mechanism of drug resistance, but this does not explain resistance in all cases. In particular, little is known about BRCA1-independent restoration of HR. Here we show that loss of REV7 (also known as MAD2L2) in mouse and human cell lines re-establishes CTIP-dependent end resection of DSBs in BRCA1-deficient cells, leading to HR restoration and PARP inhibitor resistance, which is reversed by ATM kinase inhibition. REV7 is recruited to DSBs in a manner dependent on the H2AX–MDC1–RNF8–RNF168–53BP1 chromatin pathway, and seems to block HR and promote end joining in addition to its regulatory role in DNA damage tolerance. Finally, we establish that REV7 blocks DSB resection to promote non-homologous end-joining during immunoglobulin class switch recombination. Our results reveal an unexpected crucial function of REV7 downstream of 53BP1 in coordinating pathological DSB repair pathway choices in BRCA1-deficient cells.

[1]  T. Honjo,et al.  Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme , 2000, Cell.

[2]  Facundo D. Batista,et al.  RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection , 2013, Molecular cell.

[3]  R. Wood,et al.  DNA polymerase zeta (pol ζ) in higher eukaryotes , 2008, Cell Research.

[4]  A. Ashworth,et al.  Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study , 2013, Clinical Cancer Research.

[5]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[6]  A. Lau,et al.  Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin , 2008, Clinical Cancer Research.

[7]  Shridar Ganesan,et al.  Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. , 2013, Cancer discovery.

[8]  Michael M. Murphy,et al.  Polζ ablation in B cells impairs the germinal center reaction, class switch recombination, DNA break repair, and genome stability , 2009, The Journal of experimental medicine.

[9]  Y. Murakumo,et al.  Crystal Structure of Human REV7 in Complex with a Human REV3 Fragment and Structural Implication of the Interaction between DNA Polymerase ζ and REV1* , 2010, The Journal of Biological Chemistry.

[10]  J. Sale,et al.  Sequestration of CDH1 by MAD2L2 prevents premature APC/C activation prior to anaphase onset , 2013, The Journal of cell biology.

[11]  D. Adams,et al.  53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers , 2010, Nature Structural &Molecular Biology.

[12]  E. Kohn,et al.  PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  H. Yamanishi,et al.  A Missense Mutation in Rev7 Disrupts Formation of Polζ, Impairing Mouse Development and Repair of Genotoxic Agent-induced DNA Lesions* , 2013, The Journal of Biological Chemistry.

[14]  Toshiyuki Shimizu,et al.  Structural basis of recruitment of DNA polymerase ζ by interaction between REV1 and REV7 proteins. , 2012, The Journal of biological chemistry.

[15]  D. Durocher,et al.  53BP1 is a reader of the DNA damage-induced H2A Lys15 ubiquitin mark , 2013, Nature.

[16]  S. Powell,et al.  BRCA1 and BRCA2: different roles in a common pathway of genome protection , 2011, Nature Reviews Cancer.

[17]  Alan Ashworth,et al.  Mechanisms of resistance to therapies targeting BRCA-mutant cancers , 2013, Nature Medicine.

[18]  B. Blagoev,et al.  JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1–mediated chromatin response to DNA breaks , 2013, Nature Structural &Molecular Biology.

[19]  Jeremy M. Stark,et al.  53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks , 2010, Cell.

[20]  Jiri Bartek,et al.  Human CtIP promotes DNA end resection , 2007, Nature.

[21]  R. Kanaar,et al.  DNA-binding and strand-annealing activities of human Mre11: implications for its roles in DNA double-strand break repair pathways. , 2001, Nucleic acids research.

[22]  K. Kok,et al.  REV7 is required for anaphase-promoting complex-dependent ubiquitination and degradation of translesion DNA polymerase REV1 , 2013, Cell cycle.

[23]  Ellen Fanning,et al.  A dynamic model for replication protein A (RPA) function in DNA processing pathways , 2006, Nucleic acids research.

[24]  Edward S. Miller,et al.  The RIDDLE Syndrome Protein Mediates a Ubiquitin-Dependent Signaling Cascade at Sites of DNA Damage , 2009, Cell.

[25]  T. Ørntoft,et al.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.

[26]  Peter Bouwman,et al.  A high-throughput functional complementation assay for classification of BRCA1 missense variants. , 2013, Cancer discovery.

[27]  Michal Zimmermann,et al.  53BP1: pro choice in DNA repair. , 2014, Trends in cell biology.

[28]  J. Aten,et al.  Induction of linear tracks of DNA double-strand breaks by α-particle irradiation of cells , 2008, Nature Methods.

[29]  J. Ellenberg,et al.  RNF168 Binds and Amplifies Ubiquitin Conjugates on Damaged Chromosomes to Allow Accumulation of Repair Proteins , 2009, Cell.

[30]  L. Thompson,et al.  XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. , 1999, Genes & development.